PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-224315.95%
Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
418.75%
Some D&A expansion while AXSM is negative at -0.70%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
2984.50%
SBC growth well above AXSM's 5.59%. Michael Burry would flag major dilution risk vs. competitor’s approach.
29070.41%
Working capital change of 29070.41% while AXSM is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might affect near-term cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5571250.00%
A yoy AP increase while AXSM is negative at -56.31%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
12125.42%
Growth well above AXSM's 100.00%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
753.88%
Some yoy increase while AXSM is negative at -19.79%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-298628.16%
Negative yoy CFO while AXSM is 25.25%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-260.15%
Negative yoy CapEx while AXSM is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-260.15%
We reduce yoy invests while AXSM stands at 96.15%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.